Pucotenlimab: First Approval

Jiang Y, Chen M, Nie H, et al. PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations. Hum Vaccin Immunother. 2019;15(5):1111–22.

Article  PubMed  PubMed Central  Google Scholar 

Ai L, Chen J, Yan H, et al. Research status and outlook of PD-1/PD-L1 inhibitors for cancer therapy. Drug Des Devel Ther. 2020;14:3625–49.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li H, van der Merwe PA, Sivakumar S. Biomarkers of response to PD-1 pathway blockade. Br J Cancer. 2022;126(12):1663–75.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lepu Biopharma Co., Ltd. Conditional marketing approval obtained in China for Puyouheng (Pucotenlimab injection) for the treatment in high levels of microsatellite instability/deficient mismatch repair (MSI-H/DMMR) [media release]. 22 Jul 2022.  https://en.lepubiopharma.com/upload/listedco/listconews/sehk/2022/0722/2022072200169.pdf.

Lepu Biopharma Co., Ltd., Hanx Biopharmaceuticals. Pucotenlimab: Chinese prescribing information. 2022.

Lepu Biopharma Co., Ltd. Puyouheng (pucotenlimab injection) obtains approval for marketing with a new indication, breakthrough therapy designation granted by the CDE to MRG003 for the treatment of R/M NPC [media release]. 29 Sep 2022. https://www.acnnewswire.com/press-release/english/78266/

Lepu Biopharma Co., Ltd. Post hearing information pack of Lepu Biopharma Co., Ltd. 2021. https://www1.hkexnews.hk/listedco/listconews/sehk/2022/0223/sehk22020300054.pdf. Accessed 23 Aug 2022.

Chi Med. Chi-Med enters into multiple collaborations to evaluate combinations of surufatinib and fruquintinib with PD-1 checkpoint inhibitors [media release]. 29 Nov 2018.  https://www.hutch-med.com/a181129/.

Zhang J, Huang Y, Xi G, et al. HX008: a humanized PD-1 blocking antibody with potent antitumor activity and superior pharmacologic properties. MAbs. 2020;12(1):1724751.

Article  PubMed  PubMed Central  Google Scholar 

Liu R, Li W, Meng Y, et al. Phase I study of pucotenlimab (HX008), an anti-PD-1 antibody, for patients with advanced solid tumors. Ther Adv Med Oncol. 2021;13:1–11.

Article  Google Scholar 

Huang J, Song Y, Luo S, et al. Efficacy of HX008 in high microsatellite instability/mismatch repair-deficient (MSI-H/dMMR) solid tumors: results from a multicenter phase II open-label study [abstract no. 2572]. J Clin Oncol. 2021;39(15 Suppl):2572.

Article  Google Scholar 

Song Y, Li N, Li Q, et al. HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric or gastroesophageal junction cancer: a multicenter, single-arm phase II trial. J Immunother Cancer. 2020;8(2): e001279.

Article  PubMed  PubMed Central  Google Scholar 

Xu J, Xu N, Bai Y, et al. Anti-PD-1 antibody HX008 combined with oxaliplatin plus capecitabine for advanced gastric or esophagogastric junction cancer: a multicenter, single-arm, open-label, phase Ib trial. Oncoimmunology. 2020;10(1):1864908.

Article  PubMed  PubMed Central  Google Scholar 

Zhang B, Huang J, Tang J, et al. Intratumoral OH2, an oncolytic herpes simplex virus 2, in patients with advanced solid tumors: a multicenter, phase I/II clinical trial. J Immunother Cancer. 2021;9(4): e002224.

Article  PubMed  PubMed Central  Google Scholar 

Lian B, Chen Y, Wu D, et al. Safety and efficacy of HX008: A humanized immunoglobulin G4 monoclonal antibody in patients with locally advanced or metastatic melanoma-A single-arm, multicenter, phase II study [abstract no. 9554]. J Clin Oncol. 2021;39(15 Suppl):9554.

Article  Google Scholar 

Hu XC, Cao J, Wang BY, et al. Phase 1b clinical trial of HX008, a novel anti-PD-1 monoclonal antibody, Combined with gemcitabine and cisplatin in the first-line treatment of metastatic triple-negative breast cancer [abstract no. PS12-11]. Cancer Res. 2021;81(4 Suppl):PS12-11.

Article  Google Scholar 

Cao J, Hu XC, Wang BY, et al. Update survival of phase 1b clinical trial of HX008, a novel anti-PD-1 monoclonal antibody, combined with gemcitabine and cisplatin in the first-line treatment of metastatic triple-negative breast cancer [abstract no. PO60]. Breast. 2021;59(Suppl 1):S48.

Article  Google Scholar 

Huang J, Luo S, Chen P, et al. A randomized, double-blinded, placebo-controlled phase III trial of HX008 plus irinotecan as second-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma [abstract no. 1439TiP and poster]. Ann Oncol. 2021;32(Suppl 5):S1075.

Article  Google Scholar 

留言 (0)

沒有登入
gif